Published in Leukemia on April 17, 2012
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica (2012) 1.53
How I treat plasma cell leukemia. Blood (2012) 1.46
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia (2014) 0.99
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood (2014) 0.91
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Int J Mol Sci (2015) 0.90
Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents. Rare Tumors (2012) 0.88
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia (2013) 0.87
Defining and treating high-risk multiple myeloma. Leukemia (2015) 0.80
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. Oncotarget (2016) 0.75
Plasma cell leukaemia: a management conundrum. Oxf Med Case Reports (2014) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
The molecular classification of multiple myeloma. Blood (2006) 8.77
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood (1999) 3.44
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Plasma cell leukemia. Report on 17 cases. Arch Intern Med (1974) 1.66
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Plasma cell leukemia: an evaluation of response to therapy. Am J Med (1987) 1.51
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A (1998) 39.20
A whole-genome assembly of Drosophila. Science (2000) 38.48
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Gene therapy restores vision in a canine model of childhood blindness. Nat Genet (2001) 7.88
Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science (1995) 5.65
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
A SEMI-MICRO METHOD FOR THE DETERMINATION OF REDUCING SUGARS. Plant Physiol (1940) 5.31
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Evolution of organic aerosols in the atmosphere. Science (2009) 4.82
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg (1998) 4.56
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Importance of epistasis as the genetic basis of heterosis in an elite rice hybrid. Proc Natl Acad Sci U S A (1997) 4.38
Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat Cell Biol (2001) 4.08
Complete genomic sequence of Pasteurella multocida, Pm70. Proc Natl Acad Sci U S A (2001) 3.51
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Human chromosome 19 and related regions in mouse: conservative and lineage-specific evolution. Science (2001) 3.39
Requirements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in leukocytes. J Exp Med (1997) 3.32
Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet (1996) 3.32
Detection of preinvasive cancer cells. Nature (2000) 3.20
Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet (1999) 3.19
Giant electrocaloric effect in thin-film PbZr(0.95)Ti(0.05)O3. Science (2006) 3.17
Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell (1996) 3.08
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
Relative risk trees for censored survival data. Biometrics (1992) 2.98
Advances in statistical methods to map quantitative trait loci in outbred populations. Genetics (1997) 2.90
Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature (1995) 2.88
The MYCN oncogene is a direct target of miR-34a. Oncogene (2008) 2.80
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet (1996) 2.78
Exploitation of gene(s) involved in 2,4-diacetylphloroglucinol biosynthesis to confer a new biocontrol capability to a Pseudomonas strain. Appl Environ Microbiol (1992) 2.78
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
ISOLATION OF INFLUENZA A BY INTRAALLANTOIC INOCULATION OF UNTREATED THROAT WASHINGS. Science (1943) 2.68
A review of the incorporation of complementary and alternative medicine by mainstream physicians. Arch Intern Med (1998) 2.68
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Bean abscission cellulase : characterization of a cDNA clone and regulation of gene expression by ethylene and auxin. Plant Physiol (1988) 2.47
Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology (2001) 2.46
Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology (2001) 2.43
Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain (2000) 2.41
Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst (1989) 2.31
Fluorous mixture synthesis: a fluorous-tagging strategy for the synthesis and separation of mixtures of organic compounds. Science (2001) 2.31
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart (2003) 2.25
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Patterns of cytosine methylation in an elite rice hybrid and its parental lines, detected by a methylation-sensitive amplification polymorphism technique. Mol Gen Genet (1999) 2.23
Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology (1999) 2.16
Abdominoperineal excision of the rectum--an endangered operation. Norman Nigro Lectureship. Dis Colon Rectum (1997) 2.15
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
The MITE family heartbreaker (Hbr): molecular markers in maize. Proc Natl Acad Sci U S A (2000) 2.08
Genome-wide association scan for childhood caries implicates novel genes. J Dent Res (2011) 2.05
Doctors as managers. N Z Med J (2000) 2.03
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Intrinsic fluorescence spectroscopy in turbid media: disentangling effects of scattering and absorption. Appl Opt (2001) 1.98
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat Struct Biol (1999) 1.95
Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem (1999) 1.94
Molecular characterization of a porcine enteric calicivirus genetically related to Sapporo-like human caliciviruses. J Virol (1999) 1.90
Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation (1998) 1.90
An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology (1999) 1.89
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
Stoma-related complications are more frequent after transverse colostomy than loop ileostomy: a prospective randomized clinical trial. Br J Surg (2001) 1.89
VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol (1990) 1.87
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood (2000) 1.84
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia (1999) 1.82
Chemical and microphysical characterization of ambient aerosols with the aerodyne aerosol mass spectrometer. Mass Spectrom Rev (2007) 1.80
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80
P instability factor: an active maize transposon system associated with the amplification of Tourist-like MITEs and a new superfamily of transposases. Proc Natl Acad Sci U S A (2001) 1.79
Recruitment of CREB binding protein is sufficient for CREB-mediated gene activation. Mol Cell Biol (2000) 1.78
Causes of death among people with convulsive epilepsy in rural West China: a prospective study. Neurology (2011) 1.77
Extraordinarily polymorphic microsatellite DNA in barley: species diversity, chromosomal locations, and population dynamics. Proc Natl Acad Sci U S A (1994) 1.77
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol (1993) 1.76
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma (2005) 1.75
Asthma severity and medical resource utilisation. Eur Respir J (2004) 1.74